ADC Therapeutics reported that its late-stage blood cancer drug met the primary endpoint of improved progression-free survival but showed higher mortality in treated patients, triggering a roughly 53% premarket drop. The safety signal could complicate regulatory approval, financing, and commercialization timelines, likely keeping ADCT shares highly volatile until further data clarifies risk versus benefit.
ADC Therapeutics' lead drug Zynlonta received FDA approval in 2021. Zynlonta peaked at $80 million revenue but faces strong competition. Analyst predicts Zynlonta's peak revenue could reach $110 million by 2032. Positive clinical trials may enable Zynlonta to expand into second-line treatments. Stephens initiated coverage with an Overweight rating and $6 price target.
